Recombinant Human Anti-CD33 × Anti-CD3 Bispecific Antibody (Tandem Diabody)

CAT#: TAND-LC010

The anti-CD3/CD33 antibody targets both CD3 and CD38. By T cell mediated cytotoxicity, the bispecific antibody can be potentially used in the treatment of cancers such as AML.

Specifications

  • Target
  • CD33 & CD3
  • Type
  • Tandem Diabody
  • Species Reactivity
  • Human
  • Target 1
  • CD33
  • Host Species 1
  • Human
  • Target 2
  • CD3
  • Host Species 2
  • Human
  • Application
  • FC
  • Related Disease
  • Acute myeloid leukemia

Target

  • Target 1
  • CD33
  • Alternative Names
  • CD33; CD33 molecule; p67; SIGLEC3; SIGLEC-3; myeloid cell surface antigen CD33; gp67; CD33 antigen (gp67); sialic acid binding Ig-like lectin 3; sialic acid-binding Ig-like lectin 3
  • Target 2
  • CD3
  • Alternative Names
  • CD3; CD3 T-Cell Co-receptor;CD3D; CD3E; CD3G
REVIEWS AND Q&AS CITATIONS RESOURCES DOWNLOADS RELATED PRODUCTS
Inquiry
Navs

Customer Review

Submit a review or a question

There are currently no Customer reviews or questions for TAND-LC010. Click the button above to contact us or submit your feedback about this product.
Breast cancer biomarkers at key points during disease progression
Effective AML Cell Lysis
We tested this bispecific antibody in our AML research models. It successfully bridged T cells to CD33 positive leukemic blasts, resulting in effective cell lysis. The activity was dose-dependent and specific to the presence of both target antigens.
Breast cancer biomarkers at key points during disease progression
Stable In Culture Media
Stability is a key factor for our long-duration cytotoxicity assays, and this antibody performed well. It remained active in cell culture media over several days, allowing us to observe the sustained killing effect of redirected T cells on the tumor population.

Q&As

  1. What is the intended disease model for research with this antibody?

    A: This bispecific antibody targets CD33 and CD3, making it specifically designed for research into Acute Myeloid Leukemia (AML). CD33 is a myeloid lineage marker found on AML blasts, and this tool allows researchers to test strategies for redirecting T cells to eliminate leukemic cells.

  2. Does this antibody rely on a toxin payload to kill cells?

    A: No, this is not an Antibody-Drug Conjugate (ADC) and does not carry a toxin. Instead, it functions as a T cell engager. It physically links the T cell to the tumor cell, activating the T cell's intrinsic cytotoxic machinery to kill the CD33-positive target cell.

View the frequently asked questions answered by Creative Biolabs Support.

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Article title:
DOI/PubMed URL:
Email:
Name:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Datasheet

MSDS

COA

Certificate of Analysis Lookup

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

Lot Number:

See other products for "CD33 & CD3"

Select a product category from the dropdown menu below to view related products.

CAT Product Name Application Type
FAB-L004 Recombinant Anti-CD33 × Anti-CD3 Bispecific Antibody (Fab2) FuncS, Promising therapeutic agent Fab2
Specific Inquiry
Go to compare Add to compare

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Go to compare

Go to compare